Volume 141, Issue 1, Pages 119-127 (July 2011) High-Dose Pegylated Interferon-α and Ribavirin in Nonresponder Hepatitis C Patients and Relationship With IL-28B Genotype (SYREN Trial)  Stéphane Chevaliez, Christophe Hézode, Alexandre Soulier, Bruno Costes, Magali Bouvier–Alias, Stéphanie Rouanet, Juliette Foucher, Jean–Pierre Bronowicki, Albert Tran, Isabelle Rosa, Philippe Mathurin, Laurent Alric, Vincent Leroy, Patrice Couzigou, Ariane Mallat, Mariem Charaf–Eddine, Gérard Babany, Jean–Michel Pawlotsky  Gastroenterology  Volume 141, Issue 1, Pages 119-127 (July 2011) DOI: 10.1053/j.gastro.2011.03.039 Copyright © 2011 AGA Institute Terms and Conditions

Figure 1 Flow chart of patient disposition. “Other” causes of treatment interruption include patient's decision (n = 4), investigator's decision (n = 3), and death unrelated to the study drugs (n = 1). Gastroenterology 2011 141, 119-127DOI: (10.1053/j.gastro.2011.03.039) Copyright © 2011 AGA Institute Terms and Conditions

Figure 2 Mean ± standard deviation (SD) HCV RNA level reductions from baseline in patients with a CT genotype (black circles) or a TT genotype (black squares). As a comparator, mean ± SD HCV RNA level reductions at week 12 of an earlier course of therapy with standard doses of pegylated IFN-α and ribavirin in the same patients are shown as dotted lines. P values are for CT vs TT patients. Gastroenterology 2011 141, 119-127DOI: (10.1053/j.gastro.2011.03.039) Copyright © 2011 AGA Institute Terms and Conditions